Drug Trial Radar · NCT02058147
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,170
Actual
Start
Feb 2014
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine alone and to lixisenatide alone (on top of metformin treatment) over a 30 week treatment period in participants with type 2 diabetes.
Conditions
- Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio CombinationDrug
Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
Insulin glargine (HOE901)Drug
Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
Lixisenatide (AVE0010)Drug
Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
MetforminDrug
Pharmaceutical form: Tablet; Route of administration: Oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c From Baseline to Week 30Time frame: Baseline, Week 30
Locations
273 sites in 23 countries. Site status is shown where the registry gives one.
Investigational Site Number 840027
Phoenix, Arizona
Investigational Site Number 840122
Phoenix, Arizona
Investigational Site Number 840062
Tempe, Arizona
Investigational Site Number 840023
Tempe, Arizona
Investigational Site Number 840084
Little Rock, Arkansas
Investigational Site Number 840100
Anaheim, California
Investigational Site Number 840065
Bell Gardens, California
Investigational Site Number 840090
Chino, California
Investigational Site Number 840002
Chula Vista, California
Investigational Site Number 840013
Concord, California
Investigational Site Number 840053
Fresno, California
Investigational Site Number 840017
La Jolla, California
Investigational Site Number 840070
Lancaster, California
Investigational Site Number 840121
Long Beach, California
Investigational Site Number 840126
Los Angeles, California
Investigational Site Number 840044
Los Angeles, California
Investigational Site Number 840101
Mission Hills, California
Investigational Site Number 840086
Mission Viejo, California
Investigational Site Number 840120
Mission Viejo, California
Investigational Site Number 840005
Northridge, California
Investigational Site Number 840034
Palm Springs, California
Investigational Site Number 840074
Port Hueneme, California
Investigational Site Number 840068
San Ramon, California
Investigational Site Number 840067
Santa Ana, California
Investigational Site Number 840029
Tarzana, California
Investigational Site Number 840006
Temecula, California
Investigational Site Number 840078
West Hills, California
Investigational Site Number 840059
Aurora, Colorado
Investigational Site Number 840038
Denver, Colorado
Investigational Site Number 840104
Bradenton, Florida
Investigational Site Number 840098
Miami, Florida
Investigational Site Number 840014
New Port Richey, Florida
Investigational Site Number 840047
Ocoee, Florida
Investigational Site Number 840056
Palm Harbor, Florida
Investigational Site Number 840089
Atlanta, Georgia
Investigational Site Number 840054
Lawrenceville, Georgia
Investigational Site Number 840119
Woodstock, Georgia
Investigational Site Number 840108
Idaho Falls, Idaho
Investigational Site Number 840075
Arlington Heights, Illinois
Investigational Site Number 840080
Chicago, Illinois
Showing 40 of 273 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.